https://gutsandgrowth.com/2026/09/29/podium-study-jak-inhibitors-and-ustekinumab-outperformed-vedolizumab-as-a-2nd-line-agent-for-ulcerative-colitis/gutsandgrowthen2026-09-29T11:00:00+00:00PODIUM Study: Jak Inhibitors and Ustekinumab Outperformed Vedolizumab as a 2nd Line Agent for Ulcerative ColitisUlcerative colitis, tofacitinib, Vedolizumab, ustekinumab, JAK inhibitor, Upadacitinibhttps://gutsandgrowth.com/2026/09/28/50965/gutsandgrowthen2026-09-28T11:00:00+00:00ESPGHAN Position Paper: Management of Foreign Bodies (2026)button battery, ingestion, magnet, foreign body, foreign bodies, coin, sharp, Superabsorbent polymers